Clinical Skin acquires Glytone

Clinical Skin announced on March 4 the acquisition of skin care brand Glytone from French pharmaceutical and cosmetics company Pierre Fabre Laboratories. The financial terms of the transaction were not disclosed.

It is reported that the acquisition of Glytone, a well-known skin care brand known for innovative dermatology solutions, reaffirms Clinical Skin's continued commitment to enhancing its product portfolio and expanding its influence in the cosmeceutical skin care industry.

"We are very pleased to welcome Glytone to the Clinical Skin family," said Jaime Castle, CEO of Clinical Skin. "This acquisition is fully aligned with our mission to continue to expand our offering of skin care solutions that are backed by science and innovation. Glytone's commitment to quality and efficacy complements our own values and we are excited to work together to further enhance our product offering".

Led by Pierre Fabre Laboratories for more than 20 years, Glytone has built a reputation for delivering clinically proven skin care formulas designed to address a variety of dermatological concerns, including aging, hyperpigmentation and acne treatment. Since its inception, the skin care brand has gained a loyal customer base and has proven to be a trusted product among dermatologists across the United States.

Lisa Morris, CEO of Pierre Fabre USA, said: "We are proud of the legacy we have built at Glytone over the past 20 years and believe the addition of Clinical Skin's product portfolio will allow the brand to reach new heights. We will now focus on ensuring a smooth transition for the brand that benefits patients and dermatologists alike."